Worth noting is GILD/Kite and NVS had their respective CAR-T therapies CHMP- approved in Europe, only to have NICE(UK) tell the cos. this past week that the therapies cannot be marketed/used because too costly for benefit achieved. There is concern that Germany will follow that lead.
Market Data 
Markets 
AI
